Jing Xi, MD
Hematology & Oncology · Centennial, CONPI 1275983926
Payments from drug & device makers
Across 202 payments — averaging $3681.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$523K
- Genentech, Inc.$177K
- Gilead$32K
- Stemline Therapeutics Inc.$5K
- Lilly USA, LLC$2K
- Daiichi Sankyo Inc.$431
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $523,212 |
| Genentech, Inc. | 6 | $176,829 |
| Gilead | 64 | $32,171 |
| Stemline Therapeutics Inc. | 11 | $5,022 |
| Lilly USA, LLC | 2 | $2,212 |
| Daiichi Sankyo Inc. | 11 | $431 |
| Genmab U.S., Inc. | 9 | $396 |
| Tersera Therapeutics LLC | 4 | $376 |
| GSK | 4 | $297 |
| Leica Microsystems Inc. | 1 | $280 |
| Merck | 7 | $271 |
| Novartis | 8 | $215 |
| Exelixis Inc. | 4 | $196 |
| Amgen | 2 | $188 |
| Myriad Genetic Laboratories, Inc. | 5 | $187 |
| Beigene USA, Inc. | 2 | $175 |
| Incyte Corporation | 2 | $150 |
| Tempus AI, Inc | 2 | $145 |
| Immunogen, Inc. | 1 | $135 |
| AbbVie | 2 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $100 |
| Genentech USA, Inc. | 1 | $76 |
| Johnson & Johnson | 2 | $67 |
| Eisai Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $39 |
| Bristol Myers Squibb | 1 | $34 |
| CTI Biopharma Corp. | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Pfizer | 2 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $21 |
| Menarini Silicon Biosystems, Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
How this compares
$743,640 in reported general payments places this provider in the 75th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Centennial
- David AndorskyBoulder$31.5M
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Allen CohnDenver$13.5M
- Elaine LamAurora$12.6M
- Robert RifkinDenver$11.3M
- Robert JotteLone Tree$9.4M
- Daniel PollyeaAurora$9.4M
- Henning SchadeDenver$9M
- Manali KamdarAurora$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.